The test is available to oncologists and pathologists and will benefit an estimated 24,000 patients each year in Spain.
Inbiomotion, a spin-off from IRB Barcelona and ICREA, along with Palex Medical, has introduced the MAF-TEST®, a diagnostic tool for breast cancer prognosis, to the Spanish and Portuguese markets. This pioneering test marks a notable achievement for IRB Barcelona's research, representing the first time one of its breakthroughs has resulted in a diagnostic device reaching the market.
MAF-TEST® provides oncologists with more accurate predictions of recurrence and survival rates for breast cancer patients. By pinpointing those who could benefit from bisphosphonate treatment to prevent recurrence, the MAF-TEST® offers personalised therapeutic insights that could greatly enhance patient outcomes.
With the MAF-TEST® now commercially available, IRB Barcelona's research extends its impact beyond academic circles, directly benefiting individuals affected by breast cancer through tailored treatment strategies. This achievement represents a significant milestone in the Institute's journey, reaffirming its dedication to promoting scientific excellence and making a meaningful impact.
For more information: https://www.irbbarcelona.org/en/news/institutional/irb-barcelona-icrea-spin-inbiomotion-and-palex-introduce-pioneering-test-aid
